High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

Yihong Wang; Joseph A. Sparano; Susan Fineberg; Lesley Stead; Jaya Sunkara; Susan Band Horwitz; Hayley M. McDaid

doi:10.1016/j.clbc.2012.11.003

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

Yihong Wang, Joseph A. Sparano, Susan Fineberg, Lesley Stead, Jaya Sunkara, Susan Band Horwitz, Hayley M. McDaid

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER ^- tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER^- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.

Original language	English (US)
Pages (from-to)	103-108
Number of pages	6
Journal	Clinical breast cancer
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/j.clbc.2012.11.003
State	Published - Apr 2013

Keywords

Breast cancer
Chemotherapy
Class III β-tubulin
Neoadjuvant
Predictive biomarker

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clbc.2012.11.003

Cite this

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. / Wang, Yihong; Sparano, Joseph A.; Fineberg, Susan et al.
In: Clinical breast cancer, Vol. 13, No. 2, 04.2013, p. 103-108.

Research output: Contribution to journal › Article › peer-review

@article{cf299d378d48468da89688d737aac661,

title = "High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer",

abstract = "Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.",

keywords = "Breast cancer, Chemotherapy, Class III β-tubulin, Neoadjuvant, Predictive biomarker",

author = "Yihong Wang and Sparano, {Joseph A.} and Susan Fineberg and Lesley Stead and Jaya Sunkara and Horwitz, {Susan Band} and McDaid, {Hayley M.}",

note = "Funding Information: This work was supported by National Cancer Institute Grant CA077263 , the Breast Cancer Research Foundation, the National Foundation for Cancer Research, and the National Institutes of Health Grant K12CA132783-01A1 .",

year = "2013",

month = apr,

doi = "10.1016/j.clbc.2012.11.003",

language = "English (US)",

volume = "13",

pages = "103--108",

journal = "Clinical breast cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

AU - Wang, Yihong

AU - Sparano, Joseph A.

AU - Fineberg, Susan

AU - Stead, Lesley

AU - Sunkara, Jaya

AU - Horwitz, Susan Band

AU - McDaid, Hayley M.

N1 - Funding Information: This work was supported by National Cancer Institute Grant CA077263 , the Breast Cancer Research Foundation, the National Foundation for Cancer Research, and the National Institutes of Health Grant K12CA132783-01A1 .

PY - 2013/4

Y1 - 2013/4

N2 - Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.

AB - Background: Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βIII-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. Patients and Methods: We determined βIII-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βIII-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. Results: High βIII-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P =.003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER - tumors treated with neoadjuvant chemotherapy, high βIII-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P =.021). Conclusion: This study reveals differential βIII-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βIII-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER- breast cancer, which has not been previously reported. These data provide a strong rationale for considering βIII-tubulin status and further validation of this marker in a large study.

KW - Breast cancer

KW - Chemotherapy

KW - Class III β-tubulin

KW - Neoadjuvant

KW - Predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=84875182273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875182273&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2012.11.003

DO - 10.1016/j.clbc.2012.11.003

M3 - Article

C2 - 23218766

AN - SCOPUS:84875182273

SN - 1526-8209

VL - 13

SP - 103

EP - 108

JO - Clinical breast cancer

JF - Clinical breast cancer

IS - 2

ER -

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this